Maegawa Hikoichiro, Kimura Tooru, Arii Yasuhiro, Matsui Yasuko, Kasai Soko, Hayashi Yoshio, Kiso Yoshiaki
Department of Medicinal Chemistry, Center for Frontier Research in Medicinal Science, Kyoto Pharmaceutical University, Yamashina-ku, Kyoto 607-8412, Japan.
Bioorg Med Chem Lett. 2004 Dec 6;14(23):5925-9. doi: 10.1016/j.bmcl.2004.09.034.
Towards the development of chemotherapy for the infection by human T-cell leukemia virus type I (HTLV-I), we have established evaluation systems for HTLV-I protease (PR) inhibitors using both recombinant and chemically synthesized HTLV-I PRs. Newly synthesized substrate-based inhibitors containing hydroxymethylcarbonyl (HMC) isostere showed potent anti-HTLV-I PR activity.
为了开发针对人类I型T细胞白血病病毒（HTLV-I）感染的化疗方法，我们利用重组和化学合成的HTLV-I蛋白酶（PR）建立了HTLV-I PR抑制剂的评估系统。新合成的含羟甲基羰基（HMC）等排体的基于底物的抑制剂显示出强大的抗HTLV-I PR活性。
